Express Scripts headquarters, one of the largest U.S. pharmacy benefits management companies, in Berkeley, Mo., in 2011. Jeff Roberson/AP Photo
The Federal Trade Commission (FTC) and pharmacy benefit manager Express Scripts, Inc. have reached what the FTC called a landmark settlement of a lawsuit brought by the agency, alleging that the company artificially inflated insulin drug prices.
According to a Feb. 4 FTC statement, Express Scripts will now be required to adopt “fundamental changes to its business practices that increase transparency.”
